US2022331339A1PendingUtilityA1

Compositions and methods for treating eyes and methods of preparation

63
Assignee: OCULAR SCIENCE INCPriority: May 4, 2017Filed: Apr 18, 2022Published: Oct 20, 2022
Est. expiryMay 4, 2037(~10.8 yrs left)· nominal 20-yr term from priority
A61K 31/167A61P 27/02A61K 31/382A61K 31/498A61K 31/573A61K 31/407A61K 31/216A61K 31/4709A61K 31/496A61K 31/137A61K 31/5377A61K 31/5575A61K 9/0048
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Pharmaceutical compositions, methods for treating various issues of the eyes, and methods of preparing such compositions are described. These pharmaceutical compositions may be for treating glaucoma, in preparation of eye surgery, during eye surgery, various post-op care (e.g., after cataract surgery, laser eye surgery, and the like), for treating dry eyes, and/or for promoting eyelash growth. These pharmaceutical compositions may comprise such active ingredients (APIs) as: timolol, latanoprost, brimonidine tartrate, dorzolamide, moxifloxacin HCl, dexamethasone PO 4 , phenylephrine HCl, lidocaine HCl, ketorolac tromethamine, bromfenac, prednisolone PO 4 , gatifloxacin, amniotic cytokine extract (ACE), prostaglandin E2 (PGE2), and combinations thereof.

Claims

exact text as granted — not AI-modified
1 - 40 . (canceled) 
     
     
         41 . A pharmaceutical composition comprising: phenylephrine HCl, lidocaine HCl, and ketorolac tromethamine. 
     
     
         42 . The pharmaceutical composition of  claim 41 , wherein the pharmaceutical composition comprises: phenylephrine HCl 1.5%, lidocaine HCl 1%, and ketorolac tromethamine 0.3%, wherein these percentages are with respect to weight per volume. 
     
     
         43 . The pharmaceutical composition of  claim 42 , further comprising an isotonic buffer. 
     
     
         44 . The pharmaceutical composition of  claim 42 , further comprising sodium chloride. 
     
     
         45 . The pharmaceutical composition of  claim 42 , wherein the pharmaceutical composition has a pH of 6.5. 
     
     
         46 . The pharmaceutical composition of  claim 42 , wherein the pharmaceutical composition is preservative-free. 
     
     
         47 . A pharmaceutical composition comprising: phenylephrine HCl, lidocaine HCl, and bromfenac. 
     
     
         48 . The pharmaceutical composition of  claim 47 , wherein the pharmaceutical composition comprises: phenylephrine HCl 1.5%, lidocaine HCl 1%, and bromfenac at 0.01%. 
     
     
         49 . The pharmaceutical composition of  claim 47 , wherein the pharmaceutical composition comprises: phenylephrine HCl 1.5%, lidocaine HCl 1%, and bromfenac at 0.07%. 
     
     
         50 . The pharmaceutical composition of  claim 47 , further comprising an isotonic buffer. 
     
     
         51 . The pharmaceutical composition of  claim 47 , further comprising sodium chloride. 
     
     
         52 . The pharmaceutical composition of  claim 47 , wherein the pharmaceutical composition has a pH of 7.0 to 7.2. 
     
     
         53 . The pharmaceutical composition of  claim 47 , wherein the pharmaceutical composition is preservative-free. 
     
     
         54 . A delivery device comprising a pharmaceutical composition comprising: phenylephrine HCl, lidocaine HCl, and ketorolac tromethamine. 
     
     
         55 . The delivery device of  claim 54 , wherein the pharmaceutical composition comprises: phenylephrine HCl 1.5%, lidocaine HCl 1%, and ketorolac tromethamine 0.3%, wherein these percentages are with respect to weight per volume. 
     
     
         56 . A method for treating an ocular condition of an eye; comprising administering the pharmaceutical composition of  claim 41  at, in, or around the eye via a delivery device and per a predetermined dosing regimen. 
     
     
         57 . The method of  claim 56 , wherein the pharmaceutical composition comprises: phenylephrine HCl 1.5%, lidocaine HCl 1%, and ketorolac tromethamine 0.3%, and wherein these percentages are with respect to weight per volume. 
     
     
         58 . The method of  claim 56 , wherein the pharmaceutical composition is preservative-free. 
     
     
         59 . The method of  claim 56 , wherein the pharmaceutical composition is administered in pre-operation in preparation for, during or after an eye surgery. 
     
     
         60 . The method of  claim 59 , wherein the eye surgery is a cataract surgery. 
     
     
         61 . The method of  claim 56 , wherein the predetermined dosing regimen is once per day, twice per day, three times per day, once every other day, once per week, once every other week, or once monthly.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.